Innovative platform trial revolutionizes ALS research by testing multiple treatments simultaneously, offering new hope ...

The studies tested pridopidine, CNM-Au8, verdiperstat, and zilucoplan (Zilbrysq) in the HEALEY ALS platform trial.

While main results from a platform study of four experimental drugs for amyotrophic lateral sclerosis are negative, it shows ...

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M.

NEW research has shown that pridopidine, a sigma-1 receptor agonist, does not exhibit a significant impact on the progression of amyotrophic lateral sclerosis (ALS) over a 24-week period.

Massachusetts General Hospital coordinated the first four platform trials within the HEALEY ALS platform to evaluate ...

ALS candidates from Biohaven, Prilenia, Clene and UCB have all failed to halt disease progression versus placebo in the ...

Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 ...

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), a ...

All four trials, part of the Massachusetts General Hospital’s HEALEY ALS platform trial (NCT05136885), failed to show an impact on ALS disease progression. The platform trial is examining ...